At a glance
- What the study gets you
- Health checks and monitoring — no treatment given
- Type of study
- Observational (no treatment given)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Standard echocardiography (diagnostic test), High frame rate echocardiography (other)
- How long the study runs
- Study runs about 43 months (dates as stated)
- About the drug or intervention
- Standard echocardiography — diagnostic test: Patients will undergo standard echocardiography, with and without contrast · High frame rate echocardiography — other: Following standard echocardiography, the test is repeated using high frame rate ultrasound
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Observing health over time
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 25
- Started
- 2022-02-01
- Last checked
- 2025-05
Plain English Summary
What is this study?
- • Testing a new treatment for coronary artery disease
- • Clinical study - 25 participants
- • The study will compare standard ultrasound images to high frame rate ultrasound images in patients with heart disease or with a low risk of heart disease to see if a higher frame rate of ultrasound adds to the information obtained from standard ultrasound
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with coronary artery disease
Where?
- • Harrow - London North West University Healthcare NHS Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The study will compare standard ultrasound images to high frame rate ultrasound images in patients with heart disease or with a low risk of heart disease to see if a higher frame rate of ultrasound adds to the information obtained from standard ultrasound.
More detail
Following informed consent, patients recruited for the study will have an IV cannula inserted and will undergo imaging using 2 ultrasound systems. Standard clinical system (Philips IE33) will be used for 2D and CE imaging, followed by imaging using the Verasonics VantageTM research system (Verasonics Inc., Redmond, WA), using both conventional 2D and HFR modes. Baseline unenhanced 2D and Doppler images would initially be acquired using Philips IE33 system and Verasonics VatangeTM unenhanced conventional 2D and HFR mode . Ultrasound contrast agent (Sonovue) will be then injected via the intravenous (iv) cannula and 3 sets rest contrast images will be acquired - using the Phillips IE33, Verasonics and Verasonics VantageTM platform (conventional CE and HFR CE). Both systems will be optimised separately on each patient before and during infusion of contrast agent. When the optimal imaging and destruction parameters are set, there are not modified along the acquisition. This is followed by dipyridamole infusion and the scans being repeated during stress - 3 sets contrast images will be acquired - using the Philips IE33 and Verasonics VantageTM platform (conventional CE and HFR CE).
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
Who cannot take part
- ✗Inability to undertake pharmacological stress, ie previously known intolerance to dipyridamole;
- ✗Moderate or Severe aortic or mitral regurgitation or severe mitral stenosis;
- ✗Significant lung disease like severe COPD or lung fibrosis;
- ✗Atrial fibrillation;
- ✗Inability to provide agreement to take part;
See the full criteria
Where Is This Study? (1 UK site)
London North West University Healthcare NHS Trust
Harrow HA1 3UJ, United Kingdom
How to Get in Touch
Emma Howard, MSc
Sponsor contactCONTACT
Lasha Gvinianidze, MD
Sponsor contactCONTACT